| Closed |
S1400G |
Lung-MAP S1400G: HRRD - Talazoparib (BMN 673) |
2/7/2017 |
7/23/2018 |
85% |
|
|
| Closed |
S1400K |
Lung-MAP S1400K: c-MET Positive |
2/5/2018 |
12/21/2018 |
64% |
|
|
| Closed |
S1417CD |
Impact of Cancer on Finances |
4/15/2016 |
2/1/2019 |
100% |
|
|
| Closed |
S1207 |
Ph. III Randomized, Everolimus in high risk, hormone receptor positive, HER2 negative patients. |
9/3/2013 |
5/1/2019 |
100% |
|
|
| Closed |
S1416 |
Ph II Cisplatin +/- ABT 888 in Metastatic TNBC and/or BRCA |
7/7/2016 |
6/15/2019 |
100% |
|
|
| Closed |
S1320 |
Melanoma - Ph II Intermittent vs Continuous Dabrafenib and Trametinib BRAF Positive Melanoma |
7/22/2014 |
7/15/2019 |
100% |
|
|
| Closed |
S1312 |
PI/II Inotuzumab + CVP for R/R CD22+ ALL |
4/1/2014 |
8/2/2019 |
100% |
|
|
| Closed |
S1702 |
Ph II AL amyloidosis isatuximab |
3/8/2018 |
9/30/2019 |
100% |
|
|
| Closed |
S1400F |
Lung-MAP S1400F: Non-Match-MEDI4736 and Tremelimumab |
10/2/2017 |
3/24/2020 |
51% |
|
|
| Closed |
S1619 |
Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab |
11/3/2017 |
5/1/2020 |
100% |
|
|
| Closed |
S1607 |
T-VEC + Pembro in Adv Melanoma follow prog on PD-1 Inhibitor |
10/2/2017 |
11/1/2020 |
67% |
|
|
| Closed |
S1800A |
LUNGMAP S1800A: Non-Match Immunotherapy Combination Sub-Study |
5/17/2019 |
11/16/2020 |
100% |
|
|
| Closed |
S1602 |
BCG Strain Differences and BCG vaccination in High-Grade Non-Muscle Invasive Bladder Cancer |
2/7/2017 |
12/15/2020 |
100% |
|
|
| Closed |
S1900C |
LUNGMAP S1900C: STK11 - Talazoparib Plus Avelumab |
1/16/2020 |
12/18/2020 |
100% |
|
|
| Closed |
S1815 |
Phase III Randomized for advanced biliary tract cancers |
12/3/2018 |
2/15/2021 |
100% |
|
|
| Closed |
S1318 |
PII Blinatumomab/POMP for Elderly Ph-Neg ALL |
1/12/2015 |
9/29/2021 |
98% |
|
|
| Closed |
S1613 |
RPh II Pertuzumab+Trastuzumab vs CETIRI mCRC w/HER2 amp |
10/9/2017 |
12/31/2021 |
42% |
|
|
| Closed |
S1801 |
Ph II Ramdomization for Clinically Detectable Stage III-IV High-risk Melanoma |
12/6/2018 |
5/5/2022 |
100% |
|
|
| Closed |
S1701 |
Thymic |
8/9/2018 |
9/29/2022 |
32% |
|
|
| Closed |
S1614 |
Rando Prophylactic Antiviral HBV |
2/21/2019 |
11/15/2022 |
1% |
|
|
